1448317-86-9

Basic information

• Product Name: 3-tert-butyl-N-(3-{[1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazol-5-yl]amino}-4-methylphenyl)benzamide
• Synonyms: 3-tert-butyl-N-(3-{[1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazol-5-yl]amino}-4-methylphenyl)benzamide
• CAS NO: 1448317-86-9
• Molecular Weight: 650.821
• Mol File: 1448317-86-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-tert-butyl-N-(3-{[1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazol-5-yl]amino}-4-methylphenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-tert-butyl-N-(3-{[1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazol-5-yl]amino}-4-methylphenyl)benzamide(1448317-86-9)
• EPA Substance Registry System: 3-tert-butyl-N-(3-{[1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazol-5-yl]amino}-4-methylphenyl)benzamide(1448317-86-9)

Safety Data

• Hazardous Substances Data: 1448317-86-9(Hazardous Substances Data)

Upstream product

• 1448317-16-5 (2E)-3-amino-3-[1-(4-methoxybenzyl)-1H-pyrazol-4-yl]acrylonitrile 
• 1448317-15-4 1-(4-methoxybenzyl)-1H-pyrazole-4-carbonitrile 
• 2746-25-0 p-Methoxybenzyl bromide 
• 1448317-17-6 1-(2,2-diethoxyethyl)-1'-(4-methoxybenzyl)-1H,1'H-3,4'-bipyrazole-5-amine 
• 1448317-80-3 N-(3-bromo-4-methylphenyl)-3-tert-butylbenzamide 
• 7498-54-6 3-t-Butylbenzoic acid 
• 7745-91-7 3-bromo-4-methylaniline 

Downstream Products

• 1448317-87-0 3-tert-butyl-N-(3-{6-[1-(4-methoxybenzyl)-1H-pyrazol-4-yl]-1H-imidazo[1,2-b]pyrazol-1-yl}-4-methylphenyl)benzamide 

Relevant articles and documents

Substituted phenylimidazopyrazoles and their use

The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.